X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
Rexulti (brexpiprazole) is a 5-HT2A receptor inhibitor and 5-HT1A/D2 receptor partial agonist. It is approved for the treatment of Major Depressive Disorder.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
Rexulti (brexpiprazole) is an atypical antipsychotic & serotonin 5HT2a inhibitor. It is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): Brexpiprazole
Therapeutic Area: Neurology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Rexulti (brexpiprazole) is an partial agonist activity at serotonin 5-HT1A, which is investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).
Lead Product(s): Brexpiprazole,Sertraline Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Rexulti (brexpiprazole) is an atypical antipsychotic, is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer’s disease.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
Rexulti (brexpiprazole) has a partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is indicated for the treatment if treatment of agitation associated with alzheimer's dementia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Brexpiprazole is a dopamine D2 partial agonist, a partial agonist at serotonin 5-HT1A receptor, an antagonist at serotonin 5-HT2A/5-HT2B, and noradrenaline α1B/α2C receptors. Drug is USFDA approved for the treatment of agitation associated with alzheimer's dementia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Brexpiprazole's action is mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is indicated for the treatment if treatment of MDD or schizophrenia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Brexpiprazole-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Rexulti (brexpiprazole) action is mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is indicated for the treatment if treatment of MDD or schizophrenia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
Rexulti (brexpiprazole) is a dopamine D2 partial agonist, a partial agonist at serotonin 5-HT1A receptor, an antagonist at serotonin 5-HT2A/5-HT2B, and noradrenaline α1B/α2C receptors. Drug is USFDA approved for the treatment of agitation associated with Alzheimer's dementia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2023
Details:
Brexpiprazole (Rexulti) is an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment for schizophrenia in adults and children ages 13 years and older.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
One of co-primary endpoints of study on adjunctive Rexulti (brexpiprazole) in adults with MDD and inadequate response to ADT was new exploratory outcome focusing on positive health aspects across emotional, physical, social, and cognitive domains.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
In study, improvements from baseline on primary endpoint of Montgomery-Asberg Depression Rating Scale for patients receiving Rexulti (brexpiprazole) as adjunctive therapy were statistically greater than for those receiving adjunctive placebo (2 mg：p=0.0312，1 mg：p=0.0089).
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: OPC-34712
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
Results from a phase III clinical study for treatment of agitation in patients with Alzheimer's dementia showed that patients treated with OPC-34712 (brexpiprazole) had a statistically significantly greater reduction in agitation compared to placebo.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: OPC-34712
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck AS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
Results from a phase III clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with Rexulti (brexpiprazole) had a statistically significantly greater reduction in agitation compared to placebo.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
REXULTI (brexpiprazole) exhibits high affinity (sub-nanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors. Depending on the market, brexpiprazole's brand name is Rexulti or Rxulti.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: H. Lundbeck A/S
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg is generic equivalent of Rexulti® used to treat certain mental/mood disorders (such as schizophrenia, depression).
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2021
Details:
The observed safety and tolerability profile for patients with borderline personality disorder was consistent with the safety and tolerability profile observed for patients treated with brexpiprazole in other indications.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2021
Details:
REXULTI® OD Tablets are a dose form that quickly disintegrate in the oral cavity so that it is easy to take for patients who cannot take the tablet due to difficulty in swallowing.
Lead Product(s): Brexpiprazole
Therapeutic Area: Psychiatry/Psychology Product Name: Rexulti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
